CRL

Business profile & competitive position

Charles River Laboratories International, Inc. sits in the Healthcare sector under the Medical - Diagnostics & Research industry classification. In plain terms, it is a full-service, non-clinical global drug-development partner. Its work spans research-model technologies, discovery and safety-assessment services (both GLP and non-GLP), and manufacturing-support products and services. The company reports through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. In 2025, total revenue was $4.0 billion, split 21.1% RMS, 59.8% DSA, and 19.1% Manufacturing.

The numbers currently paint a mixed picture of competitive strength. A net margin of -6.0% and an ROE of -7.7% mean the business is not generating a profit or positive return on shareholders' equity right now. That is hard to reconcile with the idea of a durable pricing-power moat in the current period. A negative P/E of -73.8 simply reflects those negative trailing earnings. On the other hand, the company operates more than 120 sites across more than 20 countries and styles itself as a "scientific partner of choice" offering an integrated portfolio. Scale, geographic reach, and the ability to support clients from target identification through non-clinical development are structural assets; they are not, however, showing up in profitability metrics at the moment.

Financial posture

Charles River's market capitalization stands at $17.2 billion, with the stock at $357.27. Because its trailing earnings are negative, the P/E ratio is negative at -73.8 and serves as a valuation signal only in the sense that the market is pricing in a recovery rather than current profitability. The net margin of -6.0% and ROE of -7.7% confirm that the firm is in a loss-making posture, while a beta of 1.40 indicates the stock has historically moved more sharply than the broad market.

Momentum indicators are strikingly strong on the price chart: the 50-day exponential moving average is $293.29, meaning the stock is trading well above that level, and the Relative Strength Index is 76.4, putting it in technically overbought territory. The supplied snapshot does not include a leverage number, so any debt analysis would require additional filings. What we can say from the provided figures is that the market is valuing CRL on a forward-looking, execution-recovery basis rather than on trailing earnings power.

Strategic priorities & outlook

According to the company's most recent 10-K, Charles River's near-term operational focus is on four fronts. First, it plans to optimize the global footprint by closing or consolidating approximately 12 additional sites over the next two years, principally in DSA and RMS. Second, it is integrating Discovery Services and Safety Assessment into one overarching DSA organization with a combined sales force and leadership approach. Third, it is pursuing the goal of being the scientific partner of choice by delivering a comprehensive and integrated portfolio to accelerate biomedical research and therapeutic innovation. Fourth, it continues to seek opportunities to expand Biologics Testing Solutions service offerings and facilities in the U.S. and Europe.

The 10-K also notes that in January 2026 the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. That acquisition fits the broader priority of securing research-animal supply chains while the footprint consolidation is intended to improve efficiency. In short, management is simultaneously cutting real estate, merging two historically separate service lines, and adding capacity in biologics testing and primate sourcing.

Macro & geopolitical exposure

As a non-clinical drug-development provider in the Medical - Diagnostics & Research industry, Charles River is exposed to the R&D spending cycles of pharmaceutical and biotechnology clients. Demand for outsourced discovery, safety assessment, and manufacturing support typically rises when biotech funding is plentiful and falls when capital tightens. Because the company operates in over 20 countries, it also faces currency-translation exposure and cross-border regulatory complexity.

The business is inherently linked to animal research, which makes it sensitive to animal-welfare regulation, activist pressure, and restrictions on the import or breeding of research animals. The Cambodia non-human primate acquisition highlights the geopolitical dimension of sourcing research models, including export controls and veterinary import rules. More broadly, changes in FDA and EMA preclinical testing standards, trade policy, tariffs on biologic materials, and global scientific talent availability can all affect costs and demand. Finally, the regulatory approval pathways for new modalities such as cell and gene therapies and regenerative medicines can shift safety-assessment requirements over time.

Recent developments

Recent news has touched on both scientific partnerships and the stock's technical momentum. On October 13, 2026, BusinessWire reported a collaboration between Charles River and Magellan Stem Cells to advance stem cell and regenerative medicine development. On October 22, 2026, BusinessWire also reported that Charles River, Labcorp, and the FDA are collaborating to validate new preclinical methods for abuse-potential assessment, a direct tie-in to the DSA safety-assessment business and regulatory science.

On the market side, DefenseWorld.net reported on October 15, 2026, that the share price had crossed above its 200-day moving average. In addition, SeekingAlpha.com included Charles River in Ariel Fund's Q3 2026 leaders and laggards list on October 26, 2026, signaling institutional-sector attention. The confluence of partnership headlines and technical attention arrived while the stock was already extended: at $357.27, with an RSI of 76.4 and a 50-day EMA of $293.29, much of the positive near-term sentiment appears to be reflected in price.

Earnings behavior & post-earnings drift

Charles River has beaten earnings expectations in each of the last eight reported quarters, a 100% beat rate, with an average earnings surprise of 9.3%. Over the same period, the average 5-day price move following the release was +1.24%, classified as an upward post-earnings drift.

The last four reports show how volatile the post-earnings price action can be even when the underlying result beats estimates. On August 5, 2026, the company reported $3.02 versus a $2.74 estimate (10.2% surprise), and the stock rose 1.84% the next day and 9.07% over the following five sessions. On May 7, 2026, CRL reported $2.06 versus $1.96 (5.1% surprise), but the stock fell 2.23% the next day and 12.42% over the next five days. Before that, on February 18, 2026, a $2.39 actual versus $2.33 estimate (2.6% surprise) produced a 3.95% one-day gain and a 6.05% five-day gain. On November 5, 2025, the company delivered $2.43 versus $2.32 (4.7% surprise), and the stock moved up 1.9% the next day and 2.27% over five sessions.

The next report is scheduled for November 4, 2026, before the market opens, with a consensus EPS estimate of $2.97. The market's real expectation is essentially anchored around that figure. Given the 8/8 beat streak and the current RSI of 76.4, an inline or modest beat on November 4 may already be anticipated, and the direction of any post-earnings drift will likely depend on guidance and margin commentary as much as on the headline number.

For a deeper dive into how institutional analysts are weighing the strategic turnaround, the November 2026 earnings setup, and the current technical backdrop, readers should review the full institutional verdict on Charles River Laboratories.